Pharmaceutical Growth Amidst Global Challenges: An ICRA Forecast
Leading domestic pharmaceutical firms are projected to see a revenue increase of 7-9% in FY2026, driven by domestic and European market growth, despite challenges in the US market. Operating profit margins are expected to remain stable, supported by favorable material prices and a focus on specialty products.
- Country:
- India
The revenue for major domestic pharmaceutical companies is forecasted to rise by 7-9 percent this fiscal year, despite facing global challenges and regulatory uncertainties in the US, according to ratings firm ICRA.
ICRA projects that in FY2026, these companies will see growth of 7-9 percent, supported by an 8-10 percent rise in domestic market revenue, along with a 10-12 percent increase in Europe.
However, the US market growth is anticipated to slow down to 3-5 percent year-on-year, compared to nearly 10 percent in FY2025. Operating profit margins are expected to maintain a resilient 24-25 percent, thanks to favorable raw material prices, better operating leverage, and a growing share of specialty products.
(With inputs from agencies.)
Advertisement
ALSO READ
Capacit'e Infraprojects Lands Rs 1,518 Crore Mumbai Housing Contract
PharmaAdda: Navigating India's Booming Pharmaceutical Industry
Turkey Warns of Tensions as Cyprus Acquires Israeli Defence System
BJP Accuses Rahul Gandhi of Undermining Democracy with 'Vote Chori' Claims
Gehlot Accuses BJP of Neglecting Tribal Legacy
Google News